Full Text
Cost-Effectiveness of Durvalumab after Chemoradiation in Stage III Non-Small Cell Lung Cancer (Nsclc)

Abstract

Authors

SD Criss MJ Mooradian MA Lumish KL Reynolds CY Kong

Back to Volume 21, Supplemental S2
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×